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The ability to expand normal pancreatic islet
β cells in culture would significantly advance
the prospects of cell therapy for diabetes. A
number of growth factors can stimulate limited
islet cell replication, however other factors may
exist which are more effective β-cell-specific
mitogens. The search for novel β-cell growth
factors has been hampered by the lack of a β-
cell-specific proliferation assay. We developed a
simple and sensitive assay for β-cell growth fac-
tors based on a conditionally-transformed
mouse β-cell line (βTC-tet). These cells express
the SV40 T antigen (Tag) oncoprotein under
control of the tetracycline (Tc) operon regula-
tory system. In the presence of Tc, Tag expres-
sion is tightly shut off and the cells undergo
complete growth arrest. Here we show that the
growth-arrested cells can proliferate in
response to growth factors in the absence of
Tag. Using this assay, a number of growth fac-
tors previously shown to be mitogenic to a
mixed islet cell population were found to
induce proliferation of pure β cells. We con-
clude that growth-arrested βTC-tet cells can be
employed in a survey of factors from various
sources for identifying novel factors with β-cell
mitogenic activity. 
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INTRODUCTION
Beta-cell transplantation represents an
attractive approach for replacement of the
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1560-4284/02 $12.00 + .00damaged β cells in type I diabetes. One major
obstacle to β-cell therapy is the lack of an abun-
dant cell supply. A number of rodent β-cell lines
have been developed by oncogenic transforma-
tion, however this approach has proven diffi-
cult to adapt to human β cells. Development of
efficient ways for in vitro expansion of normal
islets would significantly advance the prospects
of diabetes cell therapy. Adult islet cells are dif-
ficult to propagate in culture, although they
maintain a proliferative capacity, as evidenced
by a limited mitogenic response to a number of
growth factors [1,2]. Members of the growth
hormone family, in particular placental lacto-
gen (PL) and prolactin (PRL), induce replica-
tion in neonatal rat islet cells [3]. These activi-
ties may be responsible for islet mass expansion
in pregnancy. Significant mitogenic effects of
hepatocyte growth factor (HGF) have been
observed on human fetal and adult islets [4]
and mouse islets [5]. Insulin–like growth fac-
tors (IGF) I and II, and platelet-derived growth
factor, affect fetal rat islet cell growth [6,7].
IGF I has also been shown to stimulate replica-
tion of cultured rat insulinoma cells [8], and
IGF II activates the growth of both normal [9]
and transformed [10] mouse β cells in vivo. The
Reg protein, produced by pancreatic acinar
cells and regenerating islets, is another candi-
date for a β-cell growth factor [11]. These find-
ings suggest that islet cells possess cell surface
receptors and signal transduction pathways
that render them responsive to these factors. 
The search for novel β-cell growth factors
has been hampered by the lack of a specific
assay for β-cell proliferation. Normal islet cells
are difficult to isolate reproducibly and in large
numbers, and they contain various cell types, in
addition to β cells. Conventional β-cell lines are
not suitable for such an assay since their prolif-
eration is largely independent of exogenous
growth factors. In response to growth factors,
most  β-cell lines manifest a very limited
increase in their proliferation [12]. We have
developed a conditionally-transformed mouse
β-cell line, denoted βTC-tet, by expression of
SV40 T antigen (Tag) in β cells of transgenic
mice under control of the tetracycline (Tc)
operon regulatory system [13]. In the presence
of Tc, Tag expression is tightly shut off and the
cells undergo complete growth arrest. Here we
show that the growth-arrested cells manifest a
potent proliferative response to a number of
growth factors, and describe a simple and sen-
sitive assay that can serve to screen for novel
factors with potential β-cell mitogenic activity. 
MATERIALS AND METHODS
CELL CULTURE
The generation of the βTC-tet line has been
previously described [13]. Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM)
containing 25 mM glucose and supplemented
with 15% horse serum, 2.5% fetal bovine
serum (FBS), 2 mM L-glutamine, 100 U per ml
penicillin, and 100 µg per ml streptomycin (all
media supplies were from Beit-Haemek
Biological Industries, Israel). Growth arrest
was induced by including 1 µg per ml Tc
(Sigma Chemicals) in the culture medium. All
the experiments described here were performed
with cells at passages 29-40.
CELL PROLIFERATION ASSAY
βTC-tet cells were plated into wells of 96-
well plates at 2-4X104 cells per well in the pres-
ence of Tc. Ten to 14 d later the growth-arrest-
ed cells were washed twice with PBS and prein-
cubated in DMEM containing L-glutamine and
antibiotics in the absence of serum and in the
presence of Tc. Twenty four hours later the
medium was removed, and replaced with the
same medium containing the indicated growth
factors (Sigma Chemicals), for the indicated
period of time. During the last 16 h of incuba-
tion each well was pulsed with 1 µCi [methyl-
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were then lysed in water using a Dynatec cell
harvester (Automash 2000), and the DNA was
retained on a glass fiber filter (Whatman). The
radioactivity incorporated into DNA was
quantitated with a scintillation counter. For cell
counting, 2X105 cells were plated in wells of
24-well plates. Following a 72-h treatment with
growth factors as above, the cells were stained
with trypan blue and counted in a hemocy-
tometer. Each condition was assayed in at least
3 replicates. 
RESULTS AND DISCUSSION
βTC-tet cells were shown to depend on Tag
expression for proliferation [13]. To determine
whether growth-arrested βTC-tet cells can be
induced to resume cell division in the absence
of Tag, growth-arrested cells were incubated in
the presence of a number of growth factors
with documented mitogenic effects on both
rodent and human fetal, neonatal, or adult islet
cells. The factors were assayed at physiological
concentrations previously shown to be mito-
genic to islet cells, as well as at other concen-
trations. The serum was excluded from the
assay medium to eliminate potential back-
ground from growth factors present in serum.
As shown in Figure 1, four growth factors
(EGF, PRL, PL, and IGF II) manifested a robust
mitogenic effect on growth-arrested βTC-tet
cells following a 3-d incubation with the fac-
tors in DMEM without serum. The effect was
in the range of 6-8-fold increase in thymidine
incorporation over that of growth-arrested cells
incubated in the absence of growth factors.
Four other growth factors tested (HGF, growth
hormone, IGF I, and acidic fibroblast growth
factor) manifested a considerable but more
modest mitogenic effect, in the 2-4-fold range. 
The duration of the thymidine pulse (16 h)
was established empirically, to maximize the
signal. The optimal timing of the pulse was
found to be approximately 3 days from the
onset of treatment with the growth factors
(data not shown). The doubling time of βTC-
tet cells in the absence of Tc is close to 4 days.
The entrance into cell cycle from a growth-
arrested state may involve an additional lag
period. There was a distinct increase in thymi-
dine incorporation when the cells were harvest-
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FIGURE 1
Dose-dependent proliferation of βTC-tet cells in response to
growth factors. βTC-tet cells were incubated in complete growth
medium for 10-14 d in the presence of Tc to induce growth
arrest. They were then incubated for 72 h in the absence of serum
and presence of Tc and the indicated growth factors. During the
last 16 h of incubation the cells were then pulsed with [3H]thymi-
dine, and the radioactivity incorporated into DNA was quanti-
tated. The fold stimulation was calculated by dividing the cpm
obtained with each growth factor by the cpm incorporated into
cells incubated in the presence of Tc and the absence of growth
factors. Values represent mean ± SEM of 3 separate experiments.
Typical cpm values obtained in this assay were about 5X102 cpm
for cells growth arrested in the presence of Tc and not treated
with growth factors, and 1.5X104 cpm for cells incubated in reg-
ular growth medium without Tc (both in the presence or absence
of serum). IGF I and II, human recombinant insulin-like growth
factor I and II; EGF, mouse epidermal growth factor; PRL, sheep
prolactin; PL, human placental lactogen; GH, human growth
hormone; aFGF, bovine acidic fibroblast growth factor; HGF,
human recombinant hepatocyte growth factor.ed following a 72-h exposure to the growth fac-
tors, as compared to 48 h or 96 h. This may
reflect the possibility that the growth-arrested
cells respond synchronously when stimulated
by a mitogenic activity, and there are more cells
in S-phase between 56-72 h following stimula-
tion, compared with 32-48 h or 80-96 h fol-
lowing stimulation. 
To confirm that the increase in DNA synthe-
sis reflects an increase in cell number, growth-
arrested cells were treated with the growth fac-
tor that gave the highest stimulation of DNA
synthesis, EGF at 1 µg per ml, and the increase
in cell number was quantitated. As seen in
Figure 2, the cell number doubled following a
3-d treatment, indicating that the vast majority
of cells was stimulated to divide.
The serum included in the complete growth
medium likely contains some of the growth fac-
tors shown to be mitogenic to growth-arrested
βTC-tet cells. Nevertheless, these cells can
undergo growth arrest in medium with serum.
It is possible that the concentration of these fac-
tors in the serum is too low to stimulate the
proliferation of growth-arrested cells, or that
they may be complexed with binding proteins
that influence their availability for biological
activity, as has been demonstrated for the IGFs
[14]. In contrast, in the serum-free assay medi-
um, addition of purified growth factors in the
absence of the binding proteins reveals a more
pronounced mitogenic effect (Figure 2). 
We have routinely used DMEM containing
25 mM glucose for propagation of βTC lines,
72 MILO-LANDESMAN AND EFRAT 
I NTERNATIONAL J OURNAL OF E XPERIMENTAL D IABETES R ESEARCH
FIGURE 2
Effect of EGF on cell number in growth-arrested βTC-tet cells. βTC-tet cells were incubated in complete growth medium for 10 d in the
presence of Tc to induce growth arrest. They were then incubated for 72 h in the presence of Tc, and in the absence (open bars) or
presence (closed bars) of 1 µg per ml EGF, in either complete or serum-free medium, as indicated. Cells in triplicate wells were count-
ed by hemocytometer. Values are mean ± SEM.including  βTC-tet cells, since culture in low-
glucose medium often leads to cell dedifferenti-
ation in these lines (S. Efrat , M. Surana, and N.
Fleischer, unpublished results). This long-term
exposure to high glucose concentrations does
not seem to result in glucose toxicity, as judged
by the normal insulin production and glucose
sensing maintained in βTC-tet cells for over 60
passages [15]. However, these culture condi-
tions might have been expected to confuse the
proliferation assay, since the glucose concentra-
tion used could itself have a stimulatory effect
on cell replication. In practice, glucose does not
appear to have a significant mitogenic effect in
βTC-tet cells, as demonstrated by the fact that
growth arrest of these cells occurs in the pres-
ence of 25 mM glucose. The low baseline of the
assay, which is also performed in DMEM with
25 mM glucose, is a further confirmation of the
negligible mitogenic effect of glucose in this
system. 
The results obtained with the βTC-tet cells
are mostly consistent with the reported effects
of the tested growth factors on normal islet
cells. Thus, the mitogenic effects of these fac-
tors on a mixed population of islet cells are
largely confirmed here with pure β cells. The
limited activity of growth hormone, compared
with the larger effect of PRL, is in agreement
with results obtained with homologous hor-
mones [3]. Although the heterologous human
growth hormone can stimulate rat islet cell
replication [16], most likely through the PRL
receptor, it has only a modest effect on mouse
islet cells [17]. The relatively lower mitogenic
effect of IGF I in this assay, as compared with
that of IGF II, is inconsistent with previous
results that showed similar effects of both fac-
tors on fetal rat islets [7], and with the action
of both factors through the IGF I receptor. It is
possible that βTC-tet cells express IGF binding
proteins that preferentially neutralize IGF I
activity. The considerable mitogenic effect of
HGF (4-fold) confirms previous results
obtained with human islets [4]. Lefebvre et al.
[18] suggested that the HGF effect may be due
primarily to its mitogenicity to pancreatic duct
cells, which contaminate islet preparations,
rather than to its effect on β-cell proliferation.
The findings presented here support a direct
effect of HGF on murine β cells. In this context
the results with HGF demonstrate the advan-
tage of an assay based on a population of pure
β cells, over the use of the mixed cell popula-
tion in primary islets, for assessment of β-cell
growth factor activities. 
These results demonstrate that growth-
arrested βTC-tet cells maintain a proliferative
capacity in the absence of Tag and can re-enter
the cell cycle given appropriate stimuli in a
manner similar to that of normal islet β cells.
Thus they constitute an authentic model for
assessing the effect of growth factors on normal
β-cell proliferation. These cells can replace iso-
lated islets as an abundant and pure β-cell pop-
ulation for screening agents from various
sources for potential β-cell mitogenic activities.
The thymidine incorporation assay in
microtiter plates is a simple, sensitive, and
reproducible assay which is well-suited for a
large-scale survey and for monitoring factor
purification from a crude source. Mitogenic
activities identified by this assay can then be
tested on non-transformed β cells from isolated
animal or human islets, to confirm their useful-
ness for expansion of normal islet β cells. 
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